“By providing a clear pathway for conducting clinical trials, the FDA is fostering a climate of innovation…”
- Payton Nyquvest
THE PSYCHEDELIC RENAISSANCE IS WELL UNDERWAY AND THE U.S. Food and Drug Administration (FDA) is becoming more involved. In 2017, the FDA granted breakthrough status to both methylenedioxymethamphetamine (MDMA) and psilocybin. Then in 2019, the FDA approved esketamine—a ketamine-based drug—under Schedule III as a therapy for treatment-resistant depression, and clinics can be found all over the U.S.
Now things could really get
